The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | Regorafenib in refractory biliary tract cancer

Name: Regorafenib in refractory biliary tract cancer
Uploaded: 2020-07-03T10:44:28Z
Duration: 3 min 10 s
Description: Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, explores results from a Phase II study evaluating the use of regorafenib, a tyrosine kinase inhibitor, in refractory biliary tract cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Richard D. Kim • 3 Jul 2020

ESMO WCGIC 2020

Bile Duct Cancer Gastrointestinal Cancer FOLFOX Regorafenib

ABC-06

Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, explores results from a Phase II study evaluating the use of regorafenib, a tyrosine kinase inhibitor, in refractory biliary tract cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).